DNA and low titer, helper-free, recombinant AAV prime-boost vaccination for cytomegalovirus induces an immune response to CMV-pp65 and CMV-IE1 in transgenic HLA A*0201 mice (Q47626470)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	DNA and low titer, helper-free, recombinant AAV prime-boost vaccination for cytomegalovirus induces an immune response to CMV-pp65 and CMV-IE1 in transgenic HLA A*0201 mice	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/15542207

DNA and low titer, helper-free, recombinant AAV prime-boost vaccination for cytomegalovirus induces an immune response to CMV-pp65 and CMV-IE1 in transgenic HLA A*0201 mice (English)

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/15542207

Cytomegalovirus

0 references

5

object named as

Simon F Lacey

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/15542207

6

object named as

Don J Diamond

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/15542207

author name string

Ghislaine Gallez-Hawkins

1

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/15542207

Xiuli Li

2

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/15542207

Anne E Franck

3

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/15542207

Lia Thao

4

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/15542207

John A Zaia

7

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/15542207

language of work or name

0 references

publication date

1 December 2004

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/15542207

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/15542207

23

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/15542207

6

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/15542207

819-826

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/15542207

The use of HLA class I tetramers to design a vaccination strategy for melanoma patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.048

7 January 2021

Progress and prospects: naked DNA gene transfer and therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.048

7 January 2021

Prime-boost vaccination with plasmid DNA encoding caprine-arthritis encephalitis lentivirus env and viral SU suppresses challenge virus and development of arthritis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.048

7 January 2021

DNA immunization with hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming-recombinant canarypox virus boosting induces immune responses and protection from recombinant HCV-vaccinia virus infection in HLA-A2.1-transgenic mi

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.048

7 January 2021

Prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.048

7 January 2021

Immunogenic issues concerning recombinant adeno-associated virus vectors for gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.048

7 January 2021

Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.048

7 January 2021

Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.048

7 January 2021

Adenovirally transduced dendritic cells induce bispecific cytotoxic T lymphocyte responses against adenovirus and cytomegalovirus pp65 or against adenovirus and Epstein-Barr virus EBNA3C protein: a novel approach for immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.048

7 January 2021

Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.048

7 January 2021

A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.048

7 January 2021

Use of transgenic HLA A*0201/Kb and HHD II mice to evaluate frequency of cytomegalovirus IE1-derived peptide usage in eliciting human CD8 cytokine response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.048

7 January 2021

The structure of the major immediate early gene of human cytomegalovirus strain AD169.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.048

7 January 2021

Site-directed mutation in a conserved kinase domain of human cytomegalovirus-pp65 with preservation of cytotoxic T lymphocyte targeting.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.048

7 January 2021

Kinase-deficient CMVpp65 triggers a CMVpp65 specific T-cell immune response in HLA-A*0201.Kb transgenic mice after DNA immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.048

7 January 2021

Optimised helper virus-free production of high-quality adeno-associated virus vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.048

7 January 2021

Dual-target inhibition of HIV-1 in vitro by means of an adeno-associated virus antisense vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.048

7 January 2021

Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: dependence on HLA class II restricted T(H) response.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.048

7 January 2021

H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.048

7 January 2021

Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.048

7 January 2021

Characterization of cytotoxic function of CMV-pp65-specific CD8+ T-lymphocytes identified by HLA tetramers in recipients and donors of stem-cell transplants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.048

7 January 2021

Transfer of contaminants in adeno-associated virus vector stocks can mimic transduction and lead to artifactual results

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.048

7 January 2021

AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.048

7 January 2021

DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.048

7 January 2021

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.048

7 January 2021

Packaging of human chromosome 19-specific adeno-associated virus (AAV) integration sites in AAV virions during AAV wild-type and recombinant AAV vector production.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.048

7 January 2021

Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.048

7 January 2021

Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.048

7 January 2021

Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.048

7 January 2021

Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.048

7 January 2021

Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.048

7 January 2021

Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.048

7 January 2021

Identifiers

10.1016/J.VACCINE.2004.06.048

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/15542207

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/15542207

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47626470&oldid=2163262833"